微创医疗(00853)早盘跌超5%，截至发稿，跌5.54%，报7.67港元，成交额1.57亿港元。

消息面上，微创医疗发布盈警，预计2024年度净亏损不超过2.75亿美元，同比收窄超过58%。主要因收入录得近10%的增长，特别是出海业务收入大幅增长约80%；集团持续推进落实资源聚焦，运营效率获得提升，经营费用占收入比率下降约28个百分点；及年内完成数家非核心业务的出售，带来正向收益。

小摩发表研报称，对微创医疗持积极看法，形容在中小型医疗技术领域(SMID)中，集团是多元化本地领导者，具有强大的创新能力、海外市场扩张，并且预计至2026年可扭亏为盈；又指集团仍然是该行在SMID医疗技术领域的首选。

海量资讯、精准解读，尽在新浪财经APP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.